8 results about "Rosuvastatin" patented technology

This invention discloses a process for synthesizing rosuvastatin acetone tert-butyl ester, comprising the following steps: First, compound I is dissolved in an organic solvent, compound II is added, and the reaction is stirred at room temperature. The reaction is monitored by HPLC. After the reaction is complete, the product is separated to obtain compound III. Second, a palladium catalyst is added to the organic solvent, stirred and mixed evenly, and then compound III and compound IV are added and stirred under the action of the palladium catalyst to obtain compound V. The advantages of this invention are: mild reaction conditions, the entire process is carried out at room temperature, eliminating the need for harsh conditions such as high temperature and high pressure, reducing energy consumption and equipment requirements, and making it suitable for industrial-scale production; excellent stereoselectivity, using a palladium-catalyzed reselective Heck reaction to replace the traditional Witting and Julia olefin reactions, avoiding stereoisomer byproducts, and resulting in higher purity of the target product; fewer byproducts and simpler separation.

The application relates to a lovastatin spherical crystal and a preparation method and application thereof, which comprises the following steps: under the condition that the stirring speed is 150-500 r / min, the volume ratio of a lovastatin saturated solution with a temperature of 40-75 DEG C to water is 1:2-1:100, the lovastatin saturated solution is added into water with a constant temperature of 5-35 DEG C, and then lovastatin spherical crystals are obtained. The lovastatin spherical crystal has a particle size range of 0.1-5.0 mm, a Hausner ratio of 1.08-1.15, a bulk density of 0.20-0.40 g / mL, and a compacted density of 0.20-0.45 g / mL. The anti-blocking ability of the prepared lovastatin spherical crystal is strong, the problems of filtration difficulty, poor flowability and production, storage, preparation and the like caused by the needle-like crystal habit of lovastatin are solved, the operation is simple and efficient, and the industrialized scale implementation is easy.

The present disclosure provides a combination therapy for treating a liver disease or disorder and / or a lipid disease or disorder in a subject in need thereof. Specifically, the combination therapy comprises administration of rosuvastatin and resmetirom to a subject in need thereof.

The present invention relates to a composition for cancer prevention, comprising a statin-based drug as an active ingredient, and disclosed is that a statin drug known for hyperlipidemia treatment may effectively prevent cancer progression. More specifically, a novel use of rosuvastatin is provided so as to enable providing a composition for multiple myeloma (MM) prevention for inhibiting progression from monoclonal gammopathy of undetermined significance (MGUS) to MM. In addition, the composition may exhibit a greater tumor growth inhibition effect when bortezomib and rosuvastatin are co-administered compared to when each medicine is administered alone.

A method of treating a wound may include topically administering a statin composition including a statin selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combination thereof. The statin composition may be administered in an ointment, powder, or liquid format. The method may also include topically administering one or more antimicrobial drugs and / or naltrexone.

The present application relates to a kind of traditional Chinese medicine compositions, including the following weight parts of preparation raw materials: Huanglian 15~20 parts, Fashi 15~18 parts, Gualoupi 30~45 parts, Juhong 10~15 parts, Danshen 15~20 parts, Baishu 15~20 parts.The traditional Chinese medicine composition prepared in the present application has obvious effect of resisting non-alcoholic fatty liver disease (NAFLD), compared with Rosuvastatin, can further improve the lipid accumulation and balloon-like change of liver, improve the level of triglyceride (TG), cholesterol (TC), low-density lipoprotein (LDL-C) and high-density lipoprotein (HDL-C) in blood fat, reduce liver damage index glutamic-pyruvic transaminase (ALT), inhibit the expression of inflammatory factors (TNF-alpha and IL-1beta).At the same time, the body weight of NAFLD mouse can be significantly reduced, glucose tolerance can be improved, insulin sensitivity can be improved, insulin resistance can be reduced, and the efficacy of regulating intestinal flora and increasing the abundance of intestinal Akkermansia bacteria can be achieved.